|Videos|October 12, 2022
Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
Advertisement
Advertisement
Trending on OncLive
1
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
4
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
5